Sep 28, 2026
Al Gianchetti, CEO of Nuevocor, discusses genetic cardiomyopathies, an underdiagnosed condition that might explain multigenerational heart failure. Current treatments include beta blockers, pacemakers, and heart transplants but do not alter the course of the disease. Because of multiple gene mutations, Nuevocor is...
Sep 28, 2026
Al Gianchetti, CEO of Nuevocor, discusses genetic cardiomyopathies, an underdiagnosed condition that might explain multigenerational heart failure. Current treatments include beta blockers, pacemakers, and heart transplants but do not alter the course of the disease. Because of multiple gene mutations, Nuevocor is...
Sep 14, 2026
Dr. Steffen-Sebastian Bolz, Founder of QanatPharma, emphasizes the critical role of resistance arteries, microscopic blood vessels that regulate blood flow and pressure throughout the body, in maintaining organ function. Due to their size, these resistance arteries have been overlooked but with new lab techniques, QP...
Sep 14, 2026
Dr. Steffen-Sebastian Bolz, Founder of QanatPharma, emphasizes the critical role of resistance arteries, microscopic blood vessels that regulate blood flow and pressure throughout the body, in maintaining organ function. Due to their size, these resistance arteries have been overlooked but with new lab techniques, QP...
Mar 31, 2026
Tom Looby, CEO of Conavi, is focused on developing hybrid intravascular imaging technology that combines two established modalities into a single imaging catheter to provide a comprehensive view of the coronary arteries. This eliminates blind spots when using either intravascular ultrasound (IVUS) or optical coherence...